An Act to repeal 255.056 (7); to renumber and amend 255.056 (3) (c) and 255.056 (3) (d); to amend 255.056 (1) (bg), 255.056 (1) (br), 255.056 (1) (e), 255.056 (2), 255.056 (2m) (intro.), 255.056 (2m) (b), 255.056 (3) (intro.), (a) and (b), 255.056 (4), 255.056 (5), 255.056 (6) (b) and 255.056 (6) (c); to repeal and recreate 255.056 (1) (d) and 255.056 (1) (f); to create 255.056 (1) (bd), 255.056 (1) (bm), 255.056 (1) (br), 255.056 (1) (gc) and (gm), 255.056 (1) (m), 255.056 (2g) (b), 255.056 (2h) (b) and (c), 255.056 (3) (bm), 255.056 (3m) and 255.056 (8) to (20) of the statutes; Relating to: the drug repository program.
AB969 expands and modernizes Wisconsin’s drug repository program, which allows donated prescription and nonprescription drugs and related supplies to be collected, stored, repackaged, and dispensed to eligible patients. The bill broadens key definitions, including who may donate and receive drugs, what counts as a drug, and who qualifies as a health care professional, pharmacist, practitioner, recipient, and eligible patient. It also adds detailed operational rules for donation, inventory, storage, labeling, repackaging, substitution, disposal, and recordkeeping.
The bill authorizes donations from a wide range of sources, including individuals, pharmacies, health care facilities, manufacturers, wholesalers, and certain federal or out-of-state entities. It permits participating medical facilities and pharmacies to accept donated drugs that meet packaging, expiration, and temperature-control requirements, and it allows recipients to charge limited handling fees. The bill also clarifies that participation is voluntary, provides civil and criminal immunity except for reckless, wanton, or intentional misconduct, and states that these transactions are not wholesale distribution for licensure purposes. Several provisions are designed to make the program more flexible, including cross-state participation, therapeutic substitution, and the use of identifiers in records.
In practical terms, AB969 would affect Chapter 255 of the Wisconsin Statutes by substantially revising s. 255.056 and creating new subsections governing the drug repository system. It would expand the pool of entities that can participate, impose specific quality and safety standards for donated drugs, and establish record retention and compliance obligations for recipients. The bill also updates how donated drugs are handled under federal supply-chain and returns-processor rules, while preserving state oversight through pharmacy board rules and department-established eligibility criteria.
The general sentiment reflected by the bill text is strongly supportive of expanding access to donated medications, especially for indigent, uninsured, underinsured, and public-benefit patients. The structure of the bill suggests an intent to reduce waste, improve access, and make the repository program more workable for pharmacies and health care facilities by clarifying liability protections and administrative procedures. No committee transcript or vote history was provided, so there is no recorded public debate in the supplied materials.
The main points of potential contention are likely to be operational and regulatory rather than ideological: handling fees for for-profit recipients, the breadth of eligible donors and recipients, recordkeeping burdens, substitution authority, and the extent of liability immunity. Safety concerns may also arise around repackaging, temperature-sensitive drugs, cross-state transfers, and ensuring that donated products remain unadulterated, properly labeled, and not expired. The bill addresses these issues with detailed safeguards, but those same safeguards could be a focus of scrutiny from regulators, pharmacists, manufacturers, or patient advocates.
AB969 would significantly revise Wisconsin’s drug repository statute, s. 255.056, by expanding who may donate and receive drugs, clarifying eligibility, and adding detailed requirements for storage, repackaging, labeling, disposal, and recordkeeping. It would also create new statutory definitions and compliance rules, modify liability protections, and specify that repository transactions are not wholesale distribution. The bill affects pharmacies, medical facilities, pharmacists, practitioners, donors, and eligible patients, and it ties the program more closely to federal drug supply-chain and returns-processing requirements.
The bill appears generally favorable and access-oriented, with an emphasis on reducing medication waste and increasing availability of donated drugs for patients who are indigent, uninsured, underinsured, or on public assistance. Its detailed safeguards and liability protections suggest an effort to balance access with safety and administrative feasibility. No committee discussion or voting record was provided, so there is no documented opposition or support beyond the bill’s structure and stated purpose.
Likely areas of contention include the scope of eligible donors and recipients, the allowance for handling fees by for-profit entities, the extent of civil and criminal immunity, and the administrative burden of recordkeeping and compliance. Safety and quality-control issues may also be debated, especially regarding repackaging, temperature-sensitive drugs, substitution of therapeutically equivalent products, and cross-state participation. Manufacturers, regulators, and pharmacy stakeholders may differ on how much flexibility the program should allow versus how tightly it should be controlled.